The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10206 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin-based combination therapy (ACT)

The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis

October 15, 2019 - 15:36 -- Open Access
Author(s): 
Robert J. Commons, Julie A. Simpson, Ric N. Price, et al.
Reference: 
PLoS Med 16(10): e1002928

Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We undertook a systematic review and individual patient data meta-analysis to compare the efficacies of dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine (PQ) on the risk of recurrent P. vivax.

Medical Condition: 

Extent of inappropriate prescription of artemisinin and anti-malarial injections to febrile outpatients, a cross-sectional analytic survey in the Greater Accra region, Ghana

September 30, 2019 - 13:42 -- Open Access
Author(s): 
Harriet Affran Bonful, Adolf Kofi Awua, Martin Adjuik, Doris Tsekpetse, Richard Mawuko Kofi Adanu, Pricillia Awo Nortey, Augustine Ankomah and Kwadwo Ansah Koram
Reference: 
Malaria Journal 2019 18:331, 27 September 2019

Febrile children seen in malaria hypo-endemic settings, such as the Greater Accra region (GAR) of Ghana are more likely to be suffering from a non-malarial febrile illness compared to those seen in hyper-endemic settings. The need for prescribers to rely on malaria test results to guide treatment practices in the GAR is even greater. This study was designed to investigate the factors associated with inappropriate artemisinin-based combination therapy (ACT) prescription.

Country: 

Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine

September 24, 2019 - 14:59 -- Open Access
Author(s): 
André Daher, Ghait Aljayyoussi, David G. Lalloo, et al.
Reference: 
Malaria Journal 2019 18:325, 23 September 2019

Activation of hypnozoites of vivax malaria causes multiple clinical relapses, which contribute to the Plasmodium vivax burden and continuing transmission. Artemisinin-based combination therapy (ACT) is effective against blood-stage P. vivax but requires co-administration with primaquine to achieve radical cure. The therapeutic efficacy of primaquine depends on the generation of a therapeutically active metabolite via cytochrome P450 2D6 (CYP2D6). Impaired CYP2D6 metabolism has been associated with primaquine treatment failure. This study investigated the association between impaired CYP2D6 genotypes, drug-exposure to the long-acting ACT component (schizonticidal drugs) and tolerance and efficacy.

Medical Condition: 

Rare mutations in Pfmdr1 gene of Plasmodium falciparum detected in clinical isolates from patients treated with anti-malarial drug in Nigeria

September 23, 2019 - 14:42 -- Open Access
Author(s): 
Abel O. Idowu, Wellington A. Oyibo, Sanjib Bhattacharyya, Manjeet Khubbar, Udoma E. Mendie, Violet V. Bumah, Carolyn Black, Joseph Igietseme and Anthony A. Azenabor
Reference: 
Malaria Journal 2019 18:319, 18 September 2019

Plasmodium falciparum, the deadliest causative agent of malaria, has high prevalence in Nigeria. Drug resistance causing failure of previously effective drugs has compromised anti-malarial treatment. On this basis, there is need for a proactive surveillance for resistance markers to the currently recommended artemisinin-based combination therapy (ACT), for early detection of resistance before it become widespread.

Country: 
Medical Condition: 

Efficacy and safety of dihydroartemisinin–piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial

August 27, 2019 - 21:39 -- Open Access
Tags: 
Author(s): 
Esperança Sevene, Clifford G. Banda, Victor Mwapasa, et al.
Reference: 
Malaria Journal 2019 18:277, 20 August 2019

HIV-infected individuals on antiretroviral therapy (ART) require treatment with artemisinin-based combination therapy (ACT) when infected with malaria. Dihydroartemisinin–piperaquine (DPQ) is recommended for treatment of Plasmodium falciparum malaria, but its efficacy and safety has not been evaluated in HIV-infected individuals on ART, among whom drug–drug interactions are expected. Day-42 adequate clinical and parasitological response (ACPR) and incidence of adverse events were assessed in HIV-infected individuals on non-nucleoside reverse transcriptase inhibitor-based ART (efavirenz and nevirapine) with uncomplicated P. falciparum malaria treated with dihydroartemisinin–piperaquine.

Medical Condition: 

Examination of malaria service utilization and service provision: an analysis of DHS and SPA data from Malawi, Senegal, and Tanzania

July 30, 2019 - 08:39 -- Open Access
Tags: 
Author(s): 
Cameron Taylor, Annē Linn, Wenjuan Wang, Lia Florey and Hamdy Moussa
Reference: 
Malaria Journal 2019 18:258, 29 July 2019

Ensuring universal access to malaria diagnosis and treatment is a key component of Pillar 1 of the World Health Organization Global Technical Strategy for Malaria 2016–2030. To achieve this goal it is essential to know the types of facilities where the population seeks care as well as the malaria service readiness of these facilities in endemic countries.

Quality of fixed dose artemether/lumefantrine products in Jimma Zone, Ethiopia

July 15, 2019 - 16:14 -- Open Access
Author(s): 
Sileshi Belew, Sultan Suleman, Bart De Spiegeleer, et al.
Reference: 
Malaria Journal 2019 18:236, 15 July 2019

Malaria caused by Plasmodium vivax and Plasmodium falciparum is among the major public health problems in most endemic areas of the world. Artemisinin-based combination therapy (ACT) has been recommended as a first-line treatment for uncomplicated Plasmodium falciparum malaria almost in all endemic regions. Since ineffectively regulated medicines in resource limited settings could favour infiltration of poor quality anti-malarial medicines into pharmaceutical supply chain and jeopardize a positive treatment outcome, regular monitoring of the quality of anti-malarial medicines is critical. Thus, the aim of this study was to assess the quality of fixed dose combination (FDC) artemether (ART)/lumefantrine (LUM) tablets available in Jimma zone, Ethiopia.

Country: 

Therapeutic efficacy of artesunate–amodiaquine and artemether–lumefantrine combinations for uncomplicated malaria in 10 sentinel sites across Ghana: 2015–2017

June 24, 2019 - 16:00 -- Open Access
Author(s): 
Benjamin Abuaku, Nancy O. Duah-Quashie, Lydia Quaye, Sena A. Matrevi, Neils Quashie, Akosua Gyasi, Felicia Owusu-Antwi, Keziah Malm and Kwadwo Koram
Reference: 
Malaria Journal 2019 18:206, 24 June 2019

Routine surveillance on the therapeutic efficacy of artemisinin-based combination therapy (ACT) has been ongoing in Ghana since 2005. The sixth round of surveillance was conducted between 2015 and 2017 to determine the therapeutic efficacy of artesunate–amodiaquine (AS–AQ) and artemether–lumefantrine (AL) in 10 sentinel sites across the country.

Organization: 

Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children

April 22, 2019 - 12:28 -- Open Access
Author(s): 
Monia Guidi, Thomas Mercier, Manel Aouri, Laurent A. Decosterd, Chantal Csajka, Bernhards Ogutu, Gwénaëlle Carn and Jean-René Kiechel
Reference: 
Malaria Journal 2019 18:139, 18 April 2019

The population pharmacokinetic models developed for both AS/DHA and MQ showed a large variability in drug exposure in the investigated African paediatric population.

Person: 
Continent: 

Artemisinin-based combination therapy during pregnancy: outcome of pregnancy and infant mortality: a cohort study

March 28, 2019 - 16:32 -- Open Access
Tags: 
Author(s): 
Michael Nambozi, Halidou Tinto, Umberto D’Alessandro, et al.
Reference: 
Malaria Journal 2019 18:105, 28 March 2019

Outcome of pregnancy and infant survival were similar between treatment arms indicating that any of the four artemisinin-based combinations could be safely used during the second and third trimester of pregnancy without any adverse effect on the baby.

Pages

Subscribe to RSS - artemisinin-based combination therapy (ACT)